This March, postdoctoral researcher Malick Bio Idrissou, Ph.D., headed to the 2026 PSMA & Beyond Conference to present some of the lab’s most exciting therapy work to date, supported by a trainee travel award for the meeting.

In a talk titled “Next-Generation PSMA Therapy: [161Tb]Tb-ART-101 achieves superior tumor absorbed dose and anti-tumor efficacy in advanced prostate cancer,” Malick showed how our terbium-161 agent delivers a higher tumor absorbed dose and stronger anti-tumor response than current approaches in advanced prostate cancer.

PSMA & Beyond gathers the field’s leading voices in PSMA-targeted imaging and therapy each year, making it a fitting venue for this next step in the lab’s prostate cancer program. Nice work, Malick!